ArticleACS omega2026
Stable Solid Peracetic Acid Precursor for Effective Decontamination and Reuse of Personal Protective Equipment.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The COVID-19 pandemic exposed critical vulnerabilities in the global supply chain for personal protective equipment (PPE), necessitating effective decontamination methods to enable the safe reuse of scarce resources like N95 respirators and Tyvek suits. While peracetic acid (PAA) is a potent disinfectant, its liquid form presents significant logistical challenges. This study introduces acetylperoxyborate (APB), a stable solid PAA precursor powder, as a novel solution for point-of-use PPE decontamination. APB was synthesized and characterized, demonstrating excellent thermal stability (decomposition > 140 °C) and retaining over 88% of its PAA content after accelerated aging equivalent to two years at room temperature. Comprehensive toxicity analyses confirmed the absence of residual acetic acid, aldehydes, phenolic compounds, or cytotoxic byproducts on decontaminated PPE. Scanning electron microscopy revealed no structural damage to N95 mask or Tyvek suit fibers after five disinfection cycles. Efficacy was evaluated against T4 bacteriophage, a model for enveloped viruses like SARS-CoV-2. Spray application of a 0.8% (w/v) APB solution achieved a consistent 3-log reduction (99.9%) in viral activity on PPE surfaces within 5-15 min, with efficacy unimpaired by the presence of cosmetic soils. The APB-based method requires no specialized equipment, operating via a simple ″dissolve-and-spray″ protocol. These findings position APB powder as a safe, effective, and logistically advantageous decontamination technology, offering a practical strategy for conserving PPE integrity and mitigating supply shortages during future public health crises.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.